2269 related articles for article (PubMed ID: 32835632)
21. Identification of new anti-nCoV drug chemical compounds from Indian spices exploiting SARS-CoV-2 main protease as target.
Kundu D; Selvaraj C; Singh SK; Dubey VK
J Biomol Struct Dyn; 2021 Jun; 39(9):3428-3434. PubMed ID: 32362243
[TBL] [Abstract][Full Text] [Related]
22. Finding potent inhibitors against SARS-CoV-2 main protease through virtual screening, ADMET, and molecular dynamics simulation studies.
Roy R; Sk MF; Jonniya NA; Poddar S; Kar P
J Biomol Struct Dyn; 2022 Sep; 40(14):6556-6568. PubMed ID: 33682642
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of apigenin-based biflavonoid derivatives as potential therapeutic agents against viral protease (3CLpro) of SARS-CoV-2 via molecular docking, molecular dynamics and quantum mechanics studies.
Abdizadeh R; Hadizadeh F; Abdizadeh T
J Biomol Struct Dyn; 2023; 41(13):5915-5945. PubMed ID: 35848354
[TBL] [Abstract][Full Text] [Related]
24. Development of Effective Therapeutic Molecule from Natural Sources against Coronavirus Protease.
Fadaka AO; Sibuyi NRS; Martin DR; Klein A; Madiehe A; Meyer M
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502340
[TBL] [Abstract][Full Text] [Related]
25.
Chandra A; Chaudhary M; Qamar I; Singh N; Nain V
J Biomol Struct Dyn; 2022 Sep; 40(14):6534-6544. PubMed ID: 33583328
[TBL] [Abstract][Full Text] [Related]
26. Ligand and Structure-Based In Silico Determination of the Most Promising SARS-CoV-2 nsp16-nsp10 2'-
Eissa IH; Alesawy MS; Saleh AM; Elkaeed EB; Alsfouk BA; El-Attar AMM; Metwaly AM
Molecules; 2022 Mar; 27(7):. PubMed ID: 35408684
[TBL] [Abstract][Full Text] [Related]
27. Computational investigation of potent inhibitors against SARS-CoV-2 2'-O-methyltransferase (nsp16): Structure-based pharmacophore modeling, molecular docking, molecular dynamics simulations and binding free energy calculations.
Shi L; Wen Z; Song Y; Wang J; Yu D
J Mol Graph Model; 2022 Dec; 117():108306. PubMed ID: 36063745
[TBL] [Abstract][Full Text] [Related]
28. Identification of some novel oxazine substituted 9-anilinoacridines as SARS-CoV-2 inhibitors for COVID-19 by molecular docking, free energy calculation and molecular dynamics studies.
Rajagopal K; Varakumar P; Aparna B; Byran G; Jupudi S
J Biomol Struct Dyn; 2021 Sep; 39(15):5551-5562. PubMed ID: 32720578
[TBL] [Abstract][Full Text] [Related]
29. Pharmacoinformatics approach based identification of potential Nsp15 endoribonuclease modulators for SARS-CoV-2 inhibition.
Savale RU; Bhowmick S; Osman SM; Alasmary FA; Almutairi TM; Abdullah DS; Patil PC; Islam MA
Arch Biochem Biophys; 2021 Mar; 700():108771. PubMed ID: 33485847
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis, and molecular dynamics simulation studies of quinoline derivatives as protease inhibitors against SARS-CoV-2.
Singh VK; Chaurasia H; Kumari P; Som A; Mishra R; Srivastava R; Naaz F; Singh A; Singh RK
J Biomol Struct Dyn; 2022; 40(21):10519-10542. PubMed ID: 34253149
[TBL] [Abstract][Full Text] [Related]
31. Isatin-based virtual high throughput screening, molecular docking, DFT, QM/MM, MD and MM-PBSA study of novel inhibitors of SARS-CoV-2 main protease.
Varadharajan V; Arumugam GS; Shanmugam S
J Biomol Struct Dyn; 2022 Oct; 40(17):7852-7867. PubMed ID: 33764269
[TBL] [Abstract][Full Text] [Related]
32. Multidimensional virtual screening approaches combined with drug repurposing to identify potential covalent inhibitors of SARS-CoV-2 3CL protease.
Wang Y; Gao Q; Yao P; Yao Q; Zhang J
J Biomol Struct Dyn; 2023; 41(24):15262-15285. PubMed ID: 36961210
[TBL] [Abstract][Full Text] [Related]
33.
Mohapatra PK; Chopdar KS; Dash GC; Mohanty AK; Raval MK
J Biomol Struct Dyn; 2023 Feb; 41(2):435-444. PubMed ID: 34821198
[TBL] [Abstract][Full Text] [Related]
34. Prediction of potential inhibitors against SARS-CoV-2 endoribonuclease: RNA immunity sensing.
Al-Rashedi NAM; Munahi MG; Ah ALObaidi L
J Biomol Struct Dyn; 2022 Jul; 40(11):4879-4892. PubMed ID: 33357040
[TBL] [Abstract][Full Text] [Related]
35. Targeting SARS-CoV-2 main protease: structure based virtual screening, in silico ADMET studies and molecular dynamics simulation for identification of potential inhibitors.
Uniyal A; Mahapatra MK; Tiwari V; Sandhir R; Kumar R
J Biomol Struct Dyn; 2022 May; 40(8):3609-3625. PubMed ID: 33226303
[TBL] [Abstract][Full Text] [Related]
36. Identification of potential inhibitors of SARS-COV-2 endoribonuclease (EndoU) from FDA approved drugs: a drug repurposing approach to find therapeutics for COVID-19.
Chandra A; Gurjar V; Qamar I; Singh N
J Biomol Struct Dyn; 2021 Aug; 39(12):4201-4211. PubMed ID: 32462970
[TBL] [Abstract][Full Text] [Related]
37. Virtual screening of natural products inspired in-house library to discover potential lead molecules against the SARS-CoV-2 main protease.
Garg A; Goel N; Abhinav N; Varma T; Achari A; Bhattacharjee P; Kamal IM; Chakrabarti S; Ravichandiran V; Reddy AM; Gupta S; Jaisankar P
J Biomol Struct Dyn; 2023 Mar; 41(5):2033-2045. PubMed ID: 35043750
[TBL] [Abstract][Full Text] [Related]
38. Molecular Binding Mechanism and Pharmacology Comparative Analysis of Noscapine for Repurposing against SARS-CoV-2 Protease.
Kumar N; Sood D; van der Spek PJ; Sharma HS; Chandra R
J Proteome Res; 2020 Nov; 19(11):4678-4689. PubMed ID: 32786685
[TBL] [Abstract][Full Text] [Related]
39. Structure-based virtual screening, in silico docking, ADME properties prediction and molecular dynamics studies for the identification of potential inhibitors against SARS-CoV-2 M
Mohan A; Rendine N; Mohammed MKS; Jeeva A; Ji HF; Talluri VR
Mol Divers; 2022 Jun; 26(3):1645-1661. PubMed ID: 34480682
[TBL] [Abstract][Full Text] [Related]
40. Computational basis of SARS-CoV 2 main protease inhibition: an insight from molecular dynamics simulation based findings.
Avti P; Chauhan A; Shekhar N; Prajapat M; Sarma P; Kaur H; Bhattacharyya A; Kumar S; Prakash A; Sharma S; Medhi B
J Biomol Struct Dyn; 2022; 40(19):8894-8904. PubMed ID: 33998950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]